Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.
about
Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trialsEffects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus.Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement.SGLT2 Inhibitors: Benefit/Risk Balance.Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure.Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes.Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal.Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes.New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors.Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes.Rationale and Design of the STOP-OB Study for Evaluating the Effects of Tofogliflozin and Glimepiride on Fat Deposition in Type 2 Diabetes Patients Treated with Metformin/DPP-4 Inhibitor Dual Therapy
P2860
Q33567077-7A2F605F-B7FB-40C9-BFA5-973928FA968EQ33845734-3F105A8E-84AA-4BFE-9FF4-4E441BDB50D7Q37588847-7CD2FD67-ECAB-42C3-8C20-9D001FD5055CQ38931842-10CBAB3C-E883-4035-BEA1-1995C58A346BQ39000587-4AE5B5EE-D056-4F0D-8338-79E5FE35505AQ39013664-724E8B26-E0ED-4ECA-9E77-073DA0729072Q39039079-FE1C73CB-4C8F-4A8B-8639-385B522EC1E2Q47115045-A8A81599-56C8-4164-8CE9-B539CEE90219Q49963693-EBD759C2-6971-4DC3-A12B-C4DB9220BBF8Q51733588-150499F6-2E19-4BDB-B87C-6D7142911175Q51833661-AED5C50F-AE6A-4240-90F0-AB7362A1C302Q57093464-C1C68776-7BFE-4186-BB3D-E7087172B40E
P2860
Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Effects of canagliflozin on bo ...... ype 2 diabetes over 104 weeks.
@en
Effects of canagliflozin on bo ...... ype 2 diabetes over 104 weeks.
@nl
type
label
Effects of canagliflozin on bo ...... ype 2 diabetes over 104 weeks.
@en
Effects of canagliflozin on bo ...... ype 2 diabetes over 104 weeks.
@nl
prefLabel
Effects of canagliflozin on bo ...... ype 2 diabetes over 104 weeks.
@en
Effects of canagliflozin on bo ...... ype 2 diabetes over 104 weeks.
@nl
P2093
P2860
P1476
Effects of canagliflozin on bo ...... ype 2 diabetes over 104 weeks.
@en
P2093
Albert Fung
Gary Meininger
Kaj Stenlöf
Lawrence Blonde
William Canovatchel
P2860
P304
P356
10.1080/00325481.2016.1169894
P407
P577
2016-03-22T00:00:00Z